ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $110,493,263 | -13.3% | 5,301,980 | -0.4% | 0.01% | -9.1% |
Q2 2023 | $127,443,626 | -56.8% | 5,321,237 | -66.1% | 0.01% | -21.4% |
Q1 2023 | $295,348,772 | +98.7% | 15,693,346 | +68.1% | 0.01% | -6.7% |
Q4 2022 | $148,607,055 | -21.5% | 9,334,614 | -19.3% | 0.02% | -25.0% |
Q3 2022 | $189,302,000 | +8.4% | 11,571,025 | -6.7% | 0.02% | +17.6% |
Q2 2022 | $174,701,000 | -46.5% | 12,398,957 | -8.0% | 0.02% | -34.6% |
Q1 2022 | $326,520,000 | +1.1% | 13,481,449 | -2.6% | 0.03% | +8.3% |
Q4 2021 | $323,043,000 | +22.5% | 13,840,750 | -12.8% | 0.02% | +14.3% |
Q3 2021 | $263,710,000 | -30.2% | 15,876,544 | +2.4% | 0.02% | -30.0% |
Q2 2021 | $378,024,000 | -14.8% | 15,499,138 | -9.8% | 0.03% | -21.1% |
Q1 2021 | $443,437,000 | -57.4% | 17,187,483 | -11.7% | 0.04% | -59.1% |
Q4 2020 | $1,041,023,000 | +27.8% | 19,472,914 | -1.4% | 0.09% | +13.4% |
Q3 2020 | $814,619,000 | -19.2% | 19,748,348 | -5.0% | 0.08% | -26.1% |
Q2 2020 | $1,007,706,000 | +17.5% | 20,790,304 | +2.5% | 0.11% | -6.7% |
Q1 2020 | $857,291,000 | -4.1% | 20,290,897 | -2.9% | 0.12% | +20.2% |
Q4 2019 | $893,714,000 | +9.2% | 20,890,917 | -8.2% | 0.10% | +1.0% |
Q3 2019 | $818,637,000 | +41.6% | 22,746,244 | +5.2% | 0.10% | +44.1% |
Q2 2019 | $578,033,000 | -0.3% | 21,624,888 | +0.2% | 0.07% | -1.4% |
Q1 2019 | $579,486,000 | +66.3% | 21,582,357 | +0.2% | 0.07% | +43.8% |
Q4 2018 | $348,364,000 | -10.5% | 21,543,893 | +14.9% | 0.05% | +9.1% |
Q3 2018 | $389,271,000 | +36.1% | 18,751,008 | +0.1% | 0.04% | +33.3% |
Q2 2018 | $285,914,000 | -32.0% | 18,723,895 | +0.1% | 0.03% | -34.0% |
Q1 2018 | $420,308,000 | -25.1% | 18,705,291 | +0.4% | 0.05% | -24.2% |
Q4 2017 | $560,974,000 | -18.9% | 18,630,845 | +1.5% | 0.07% | -21.4% |
Q3 2017 | $691,623,000 | +35.5% | 18,360,045 | +0.3% | 0.08% | +33.3% |
Q2 2017 | $510,582,000 | -18.5% | 18,306,966 | +0.5% | 0.06% | -21.2% |
Q1 2017 | $626,099,000 | +19.5% | 18,211,143 | +0.2% | 0.08% | +14.3% |
Q4 2016 | $523,938,000 | -9.0% | 18,167,076 | +0.4% | 0.07% | -9.1% |
Q3 2016 | $575,708,000 | +4.5% | 18,098,352 | +6.7% | 0.08% | +2.7% |
Q2 2016 | $550,828,000 | +16.6% | 16,969,451 | +0.5% | 0.08% | +15.4% |
Q1 2016 | $472,257,000 | -12.5% | 16,890,468 | +11.6% | 0.06% | -11.0% |
Q4 2015 | $539,625,000 | +8.0% | 15,136,743 | +0.2% | 0.07% | +2.8% |
Q3 2015 | $499,596,000 | -20.7% | 15,107,227 | +0.4% | 0.07% | -12.3% |
Q2 2015 | $630,068,000 | +28.7% | 15,044,613 | +0.1% | 0.08% | +30.6% |
Q1 2015 | $489,689,000 | +3.1% | 15,025,757 | +0.4% | 0.06% | 0.0% |
Q4 2014 | $475,156,000 | +28.7% | 14,965,545 | +0.3% | 0.06% | +24.0% |
Q3 2014 | $369,308,000 | +10.1% | 14,915,523 | +0.5% | 0.05% | +11.1% |
Q2 2014 | $335,313,000 | -5.8% | 14,843,448 | +1.5% | 0.04% | -8.2% |
Q1 2014 | $355,836,000 | +4.5% | 14,625,393 | +7.3% | 0.05% | +2.1% |
Q4 2013 | $340,613,000 | -7.0% | 13,629,970 | +2.3% | 0.05% | -14.3% |
Q3 2013 | $366,124,000 | +52.2% | 13,328,165 | +0.6% | 0.06% | +43.6% |
Q2 2013 | $240,573,000 | – | 13,254,735 | – | 0.04% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |